CMP Therapeutics was founded in 2004 as a 'spin-out' from Oxford University. It is based on proof of concept studies performed by Dr Peter Strong in the MRC Immunochemistry Unit. Strong proved that chitin microparticles (CMP) are useful in the treatment of infectious and allergic diseases. The Company is exploiting the potential medical uses of CMP in preventing or treating disease by delivering CMP as microgel formulations to the mucosa of the human nose and gastrointestinal tract. To date, CMP Therapeutics has received all its funds from Inventages Venture Capital and BioPacificVentures, who are the major shareholders. CMP Therapeutics registered its first product in 2011. Atlantic Secret™ is a nasal microgel spray that needs to be administered twice a day (morning and evening) for at least one month, and used when there is either; an imminent danger of contracting a cold or flu (such as when a family member or office colleague has a cold) or at the first signs and symptoms of an impending cold or flu; or during the allergy season or if in the presence of a persistent allergen, until symptoms decline. The product is classified as a Class III medical device for the European Market and targeted at the OTC market in European initially with Russia and China to follow. The European product's principle mode of action will be to act as a mucosal barrier, trapping and killing virus particles and bacteria and aiding their removal.   Press Release CMP Therapeutics gains CE mark for Novel Rhinitis product - Atlantic Secret™. Download PDF